[go: up one dir, main page]

WO2012006368A3 - Compositions et méthodes pour traiter la grippe - Google Patents

Compositions et méthodes pour traiter la grippe Download PDF

Info

Publication number
WO2012006368A3
WO2012006368A3 PCT/US2011/043095 US2011043095W WO2012006368A3 WO 2012006368 A3 WO2012006368 A3 WO 2012006368A3 US 2011043095 W US2011043095 W US 2011043095W WO 2012006368 A3 WO2012006368 A3 WO 2012006368A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
treating influenza
combination
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/043095
Other languages
English (en)
Other versions
WO2012006368A2 (fr
Inventor
David E. Anderson
Andrei Ogrel
Ronald Erwin Boch
Jeff Baxter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Variation Biotechnologies Inc
Original Assignee
Variation Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Variation Biotechnologies Inc filed Critical Variation Biotechnologies Inc
Publication of WO2012006368A2 publication Critical patent/WO2012006368A2/fr
Publication of WO2012006368A3 publication Critical patent/WO2012006368A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des compositions et des méthodes pouvant servir à traiter la grippe. Lesdites compositions et méthodes sont fondées sur le développement de certaines compositions qui renferment un antigène hémagglutinine du virus de la grippe en association avec des vésicules lipidiques qui comportent un tensioactif non ionique (NISV) et/ou en association avec un adjuvant de type agoniste du TLR-3. Dans certains modes de réalisation, les compositions restent actives même si elles ne sont pas conservées dans un système de chaîne du froid normalisé (à savoir, elles sont thermostables).
PCT/US2011/043095 2010-07-06 2011-07-06 Compositions et méthodes pour traiter la grippe Ceased WO2012006368A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36189910P 2010-07-06 2010-07-06
US61/361,899 2010-07-06
US201161431278P 2011-01-10 2011-01-10
US61/431,278 2011-01-10

Publications (2)

Publication Number Publication Date
WO2012006368A2 WO2012006368A2 (fr) 2012-01-12
WO2012006368A3 true WO2012006368A3 (fr) 2012-03-15

Family

ID=45441782

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/043095 Ceased WO2012006368A2 (fr) 2010-07-06 2011-07-06 Compositions et méthodes pour traiter la grippe

Country Status (1)

Country Link
WO (1) WO2012006368A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9849173B2 (en) 2009-07-06 2017-12-26 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
CA2803282C (fr) 2009-07-06 2018-05-01 David E. Anderson Procedes pour preparer des vesicules et formulations produites a partir de ces procedes
CN103096922B (zh) 2010-07-06 2019-08-06 变异生物技术公司 用于治疗流行性感冒的组合物和方法
EP2663327A4 (fr) * 2011-01-13 2015-12-02 Variation Biotechnologies Inc Compositions et méthodes de traitement d'infections virales
CN104302323A (zh) 2012-01-12 2015-01-21 变异生物技术公司 用于治疗病毒感染的组合物和方法
CN104244984B (zh) * 2012-01-27 2020-03-31 变异生物技术公司 用于治疗剂的方法和组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070264273A1 (en) * 2003-06-18 2007-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Sphingoid polyalklamine conjugates, isomers and uses thereof
US20100080844A1 (en) * 2002-07-05 2010-04-01 Andrew David Bacon Method to enhance an immune response of nucleic acid vaccination

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100080844A1 (en) * 2002-07-05 2010-04-01 Andrew David Bacon Method to enhance an immune response of nucleic acid vaccination
US20070264273A1 (en) * 2003-06-18 2007-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Sphingoid polyalklamine conjugates, isomers and uses thereof

Also Published As

Publication number Publication date
WO2012006368A2 (fr) 2012-01-12

Similar Documents

Publication Publication Date Title
WO2012006367A3 (fr) Compositions et méthodes pour traiter la grippe
WO2012006368A3 (fr) Compositions et méthodes pour traiter la grippe
WO2009001217A3 (fr) Vaccins antigrippaux à faible teneur en additifs
HK1201186A1 (en) Solid compositions comprising an hcv inhibitor
WO2009031043A3 (fr) Compositions comprenant des antigènes de yersinia pestis
WO2007098186A3 (fr) Compositions d'adjuvant et de vaccin
CL2014002509A1 (es) Una composicion que comprende por lo menos una fuente de boro y por lo menos una fuente de silicio; producto que comprende sustrato y la composicion; un metodo para proporcionar un producto recubierto; uso de la composicion.
WO2009085025A3 (fr) Vaccin
WO2013054199A3 (fr) Antigènes de cmv et leurs utilisations
WO2010119343A3 (fr) Compositions pour l'immunisation contre staphylococcus aureus
MX2010008799A (es) Proceso para estabilizar una composicion de vacuna que contiene adyuvante.
WO2012100224A3 (fr) Préparation de réseaux métal- triazolate
WO2008147496A3 (fr) Vaccins de la grippe vivants déficients en neuraminidase
WO2012121547A3 (fr) Composition adhésive pour un film de traitement de tranche
WO2012080833A3 (fr) Formes pharmaceutiques permettant une libération contrôlée
WO2008054481A3 (fr) Meilleures compositions de virus influenza inactivé
HK1221641A1 (zh) 疫苗组合物及使用方法
WO2013055877A3 (fr) Ensemble serrure à barillet à éléments non rotatifs
CL2013001737A1 (es) Composicion para limpieza que comprende un tensioactivo no ionico, nanoparticulas de base inorganica y un tensioactivo secundario; formulacion de limpieza lista para usarse que comprende a dicha composicion; y composicion para la limpieza de superficies duras.
WO2009120380A3 (fr) Vecteurs de rhinovirus recombinants
MX357477B (es) Composiciones de limpieza de sal colina.
WO2013111012A3 (fr) Procédés et compositions pour agents thérapeutiques
WO2014100465A3 (fr) Compositions aqueuses de cloquintocet-mexyl à température stable
MX359103B (es) Composiciones y sus usos en el tratamiento de infecciones virales.
WO2012138611A3 (fr) Agents, systèmes et procédés d'interfaçage personnalisables

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11804306

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11804306

Country of ref document: EP

Kind code of ref document: A2